Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Labeled, Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of Intravitreal AG-73305 in Patients With Diabetic Macular Edema

NCT05301751 is registered in ClinicalTrials.gov with Allgenesis Biotherapeutics Inc. as lead sponsor.

NCT NCT05301751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05301751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Labeled, Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of Intravitreal AG-73305 in Patients With Diabetic Macular Edema
Lead sponsor
Allgenesis Biotherapeutics Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 19, 2022
Completion date
December 26, 2023
Enrollment
25 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema